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Abstract. We have previously investigated, discovered, and replicated plasma protein biomarkers for use to triage potential
trials participants for PET or cerebrospinal fluid measures of Alzheimer’s disease (AD) pathology. This study sought to
undertake validation of these candidate plasma biomarkers in a large, multi-center sample collection. Targeted plasma
analyses of 34 proteins with prior evidence for prediction of in vivo pathology were conducted in up to 1,000 samples from
cognitively healthy elderly individuals, people with mild cognitive impairment, and in patients with AD-type dementia,
selected from the EMIF-AD catalogue. Proteins were measured using Luminex xMAP, ELISA, and Meso Scale Discovery
assays. Seven proteins replicated in their ability to predict in vivo amyloid pathology. These proteins form a biomarker panel
that, along with age, could significantly discriminate between individuals with high and low amyloid pathology with an
area under the curve of 0.74. The performance of this biomarker panel remained consistent when tested in apolipoprotein E
!4 non-carrier individuals only. This blood-based panel is biologically relevant, measurable using practical immunocapture
arrays, and could significantly reduce the cost incurred to clinical trials through screen failure.
Keywords: Alzheimer’s disease, amyloid-", biomarkers, plasma, proteomics
INTRODUCTION
Clinical trials for Alzheimer’s disease (AD) mod-
ification have recently started to target the earlier
prodromal and pre-symptomatic stages in the belief
that disease modification efforts are most likely to
be effective earlier in the disease process [1, 2].
However, conducting trials in prodromal/preclinical
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individuals necessitates the use of biomarkers to
detect evidence of in vivo AD pathology. Currently,
pathology detection is possible using biochemical
measures in cerebrospinal fluid (CSF) obtained from
lumbar puncture and by positron emission tomogra-
phy (PET) coupled to ligands for amyloid imaging.
Both methods are employed routinely in clinical stud-
ies but their limitations impact significantly upon the
efficiency of clinical trials. Both CSF sampling and
PET can be costly and invasive and are therefore not
suitable for large-scale screening or where repeated
measures are desirable. The relatively low prevalence
of amyloid pathology in people with mild cognitive
impairment (MCI), and even more so in cognitively
healthy individuals, inevitably results in high screen
failure rates when trying to detect prodromal or pre-
clinical AD [3]. The cost of this screen failure by
either CSF or PET can be prohibitive as well as con-
tributing to the delay in start-up of clinical trials.
More worryingly, given that such screening is likely
to be mandatory as part of clinical implementation
of a successful therapeutic, this screen failure rate is
likely to constitute an obstacle to clinical translation
through a combination of cost factors and the capacity
of health systems to enable lumbar puncture or PET
imaging at the scale likely to match demands of their
populations. One option to overcome this issue is to
employ prediction methods such as apolipoprotein
E (APOE) genotyping prior to trial entry, as APOE
!4 carriers are more likely to harbor AD pathology.
However, not all individuals with preclinical or pro-
dromal AD have an APOE !4 allele and furthermore
APOE genotyping only reveals risk and does not indi-
cate current pathological state. Therefore, in order to
increase the efficiency of recruitment to clinical tri-
als, a cost effective, minimally invasive method that
can be implemented on a large scale to predict cur-
rent AD pathology would be enormously valuable.
A blood-based assay that predicted likely pathologi-
cal load would become part of a diagnostic screening
funnel triaging potential trials participants or users of
therapy to direct markers of pathology such as CSF
measures or PET imaging.
Over a decade ago, we conducted a large agnos-
tic, or untargeted, proteome-wide, discovery study of
blood biomarkers in dementia [4]. This study was
successful in detecting a signal in the blood that
reflected the presence of AD-type dementia and since
then many other studies, by others and by ourselves,
have aimed to replicate and improve upon this orig-
inal signal and have identified blood-based protein
biomarkers able to distinguish AD-type dementia
‘cases’ from cognitively healthy elderly ‘controls’
[5]. However, the relatively low rate of replication
of individual biomarkers across studies may be in
part due to issues of a study design that compares
people with clinical AD, some of whom will not
have pathology, to cognitively healthy elderly con-
trols, many of whom will harbor silent pathology.
Other factors limiting replication include technical
issues such as assay variance and quality, differences
in sampling and storage protocols and the frequently
small size of many studies [6, 7]. Nonetheless, such
studies demonstrate that there is a signature of dis-
ease detectable in blood and the task is now to find a
signature that is reproducible.
To address this, we have gradually refined our
study design, focusing on an ‘endophenotype’
approach predicating on outcomes not of clinical
diagnosis, but of a phenotype indicative of dis-
ease such as brain atrophy measured by structural
MRI or amyloid-" (A") plaque burden measured
by PET and CSF. Using this approach, we have
identified putative plasma markers relating to in
vivo AD pathology and disease progression using a
range of proteomic approaches including mass spec-
trometry, SOMAscan, and immunocapture [8–15].
In addition, we also performed a series of iterative
studies targeting complement and related inflam-
matory proteins; neuroinflammation itself being an
endophenotype associated with disease and amyloid
pathology [16]. Many of the proteins identified in
these discovery-phase ‘endophenotype’ studies repli-
cate across proteomic platforms and different cohort
types. However, unsurprisingly given the wide range
of techniques and study designs, not every protein
identified replicates in every study. The aim of the
present study was to determine the most replica-
ble set of plasma protein markers predicting in vivo
brain amyloid pathology, by testing 31 of our pre-
viously discovered candidate biomarkers in a large,
multi-center cohort of individuals with high and low
amyloid burden.
METHODS
Subjects: EMIF-AD Multimodal Biomarker
Discovery study (EMIF-AD MBD) cohort
The EMIF-AD MBD is part of the European
Medical Information Framework for Alzheimer’s
Disease (EMIF-AD; http://www.emif.eu/), a Euro-
pean wide collaboration to facilitate the re-use of
existing healthcare data and the sharing of cohort
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samples for the benefit of AD research. The EMIF-
AD MBD study design, including subject selection
criteria, clinical diagnoses, brain amyloid classifi-
cation, and plasma sample collection have all been
described previously [17]. In essence though, we
sought to assemble a collection of samples from par-
ticipants in cohort studies from across the full clinical
disease spectrum from preclinical through prodro-
mal to advanced disease, in each category seeking
to balance those with amyloid pathology to those
without. To do this we selected, using existing data,
samples for inclusion from apparently normal, cog-
nitively healthy elderly controls, from participants
with diagnosed MCI and from people with estab-
lished AD-type dementia. Samples were selected
within each category with proven high and low
amyloid load as previously described [17]. Overall,
1,221 participants were recruited to the EMIF-AD
MBD study from 11 European cohorts. Each par-
ent cohort was approved by the local medical ethics
committee.
The present study selected two sub-cohorts of par-
ticipants from the EMIF-AD MBD study, all with
plasma samples available for analysis. Firstly, 1,000
individuals comprising 408 cognitively healthy indi-
viduals, 400 individuals with MCI, and 192 AD-type
dementia patients were included for proteomic analy-
sis in the University of Oxford laboratories. Secondly,
866 individuals (93 AD, 413 MCI, 360 control) were
included for proteomic analysis in the laboratories at
Cardiff University. 679 (78%) of the Cardiff sam-
ple set were also included in the Oxford sample
set. Participants were included in these ‘Oxford’ and
‘Cardiff’ sample sets from across three multi-center
studies: DESCRIPA [18], EDAR [19], and Pharma-
Cog [20], and eight single center studies: Amsterdam
[21], Antwerp [22], San Sebastian GAP [23], Gothen-
burg [24], Barcelona IDIBAPS [25], Lausanne [26],
Leuven [27], and Barcelona St Pau [28]. Sample num-
ber differences between the ‘Oxford’ and ‘Cardiff’
sample sets were necessary due to plasma sample
availability. Differences in the distribution of partic-
ipants across multiple diagnostic categories between
the ‘Oxford’ and ‘Cardiff’ sample sets are displayed
in Supplementary Figure 1. The methods for address-
ing the challenge these differences presented are
described in full in Bos et al. [17].
Plasma analyses
Targeted plasma protein analyses were conducted
at both Oxford and Cardiff laboratories using
Luminex xMAP (Cat#: HNDG1MAG-36K-06,
HNDG2MAG-36K-05, HNDG3MAG-36K-07, HN
D2MAG-39K-02, HKI6MAG-99K-03, HNDG1
MAG-36K-01), ELISA (Cat#: CSB-EL008551HU
and CSB-E13319H), and MSD assays (in-house
optimized using U-plex platform). All assays were
performed according to the manufacturer’s instruc-
tions. Overall, concentrations of 25 proteins were
determined at Oxford while 6 proteins were analyzed
at Cardiff.
Brain amyloid measurements and group
classifications
Measurement and classification of in vivo amy-
loid burden in the EMIF-AD MBD cohort has been
described previously [17]. Briefly, where CSF was
available, A"1-40 and A"1-42 were measured using
the V-PLEX Plus A" Peptide Panel 1 (6E10) Kit
from Meso Scale Discovery in a central laboratory
(Gothenburg University, Sweden) and the A"42/40
ratio was established. The A" group was defined
by the A"42/40 ratio, using a cut-off of <0.063 to
determine abnormality. Where CSF samples were
unavailable, then the locally measured CSF A"42
value and cut-off point provided by the parent cohort
or the standardized uptake value ratio (SUVR) and
cut-off point from an amyloid PET scan was used.
The above measurements were combined into a
continuous variable using z-scoring. The A" Z-score
was calculated using the mean and standard devia-
tion of the control subjects as a reference. In cases
where an individual had multiple measures of amy-
loid (e.g., CSF and PET), all data available were
used to generate the mean and standard deviation
for each measure. However, the measure included in
the final A" Z-score was selected from each individ-
ual in the following order of priority: CSF A"42/40
ratio, local CSF A"42, or the amyloid PET SUVR.
PET amyloid Z-scores were multiplied by –1 in
order to be combined with CSF derived amyloid
Z-scores.
CSF tau measurements
To assess in vivo tau pathology, continuous phos-
phorylated tau (p-tau) and total tau (t-tau) values were
obtained from the parent cohorts [17]. As sites were
not standardized to each other, the p-tau and t-tau val-
ues were Z-scored with controls within each data set
as a reference.
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MRI data
Full details on the MRI data acquisition, visual rat-
ing check, and region of interest measurements have
been previously reported [17]. Briefly, TI-weighted
images, acquired according to local protocols, were
collected from each site, each image was visually
assessed and Freesurfer used to obtain volumetric
measurements.
Clinical and cognitive data
Baseline clinical information and neuropsycho-
logical test scores were collected from each local
site, harmonized, pooled and stored in an online data
platform using tranSMART [29]. Full details of the
clinical information provided by each site and the
harmonization process has been previously described
[17].
In all cohorts, a diagnosis of AD-type demen-
tia was made according to the National Institute
of Neurological and Communicative Disorders and
Stroke-Alzheimer’s Disease and Related Disorders
Association (NINCDS-ADRDA) criteria [30]. The
Petersen criteria [31] was used to diagnose MCI in
nine cohorts, while two cohorts used the Winblad
et al. criteria [32] for this diagnosis. Normal perfor-
mance on neuropsychological assessment (1.5 SD of
the average for age, gender, and education) was used
by all cohorts to define cognitively healthy individu-
als. Further details describing the diagnostic criteria
used by each cohort can be found in Bos et al. [17].
For those individuals with MCI at baseline, we
identified their clinical diagnosis at the last avail-
able follow-up visit provided by each local site
(average = 2.21 years). Those that changed in their
diagnosis to AD-type dementia, or had a decrease of
at least 3 Mini-Mental State Examination (MMSE)
points, were classed as MCI-convertors. MMSE was
provided for all individuals.
Apolipoprotein E (APOE) genotyping
APOE genotypes for single nucleotide polymor-
phisms (SNPs) rs429358 and rs7412 were either
determined from genome-wide SNP genotyping data
(generated via the Infinium Global Screening Array
(GSA) with Shared Custom Content, Illumina Inc.)
or by TaqMan assays (ThermoFisher Scientific, Fos-
ter City, CA) on a QuantStudio-12K-Flex system
in 384-well format. After QC, there were sufficient
data to classify 926 individuals as APOE !4 carriers
or non-carriers according to their genotype status at
rs429358 (C-allele = !4). Missing values for APOE
!4 status were imputed using regression analyses
within study, based on significant predictors (age,
gender, MMSE, cognitive scores) [17].
Statistical analyses
All statistical analyses were completed using R
(version 3.3.2) and all statistical tests were two-tailed.
Individual participant data was excluded where there
was a long interval (>1 year), or missing data on the
time interval, between plasma collection and mea-
surement of the outcome variable (amyloid status,
n = 69 and 30 excluded from Oxford and Cardiff sam-
ple sets, respectively; MMSE, n = 73 and 39 excluded
from Oxford and Cardiff, respectively; brain vol-
ume, n = 121 and 97 excluded from Oxford and
Cardiff, respectively). Baseline cohort characteristics
between high and low amyloid groups were compared
using Mann-Whitney U test. All regression analy-
ses included age as a covariate. p-values and false
discovery rate corrected q-values are reported.
Univariate statistics
Univariate statistics were performed using iden-
tical statistical methods for both the ‘Oxford’ and
‘Cardiff’ sample sets and the results for all 31 proteins
are presented in this manuscript together. The rela-
tionship of each individual protein with group-wise
outcome variables was tested using logistic regres-
sion. The relationship of proteins with continuous
outcome variables was examined using linear regres-
sion.
ROC analysis was performed on each protein
individually, and the outcome was the dichotomous
amyloid status. Sensitivity, specificity and area under
the curve (AUC) metrics were computed. The 95%
confidence intervals were estimated using the boot-
strap resampling method with n = 1000 repetitions
[33]. The optimal operation point from the ROC curve
was identified by maximizing the Youden’s J statistic
[34].
Multivariate amyloid classifier
Logistic regression was used to assess the perfor-
mance of a multi-protein model for the discrimination
between individuals in the abnormal and normal brain
amyloid groups. The AUC, sensitivity, specificity,
and likelihood ratio (LR) of the model are reported.
The optimal operation point from the ROC curve was
identified by maximizing the Youden’s J statistic [34].
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Table 1
Demographics of subjects from the EMIF-AD MBD study
Variable Subjects included in Subjects included in
Oxford sample set Cardiff sample set
Normal Abnormal p Low High p
amyloid amyloid amyloid amyloid
status status status status
N 457 543 / 460 406 /
A" Z-score 0.49± 0.62 –1.35± 0.48 <0.001∗ 0.45± 0.62 –1.36± 0.51 <0.001∗
Age (y) 66.52± 8.71 69.81± 8.12 <0.001∗ 66.61± 8.25 70.47± 8.22 <0.001∗
Female gender N (%) 223 (49) 301 (55) <0.05∗ 253 (55) 226 (56) 0.844
CTL N (%) 289 (63) 119 (22) / 272 (59) 88 (22) /
MCI N (%) 147 (32) 253 (47) / 179 (39) 234 (58) /
AD N (%) 21 (5) 171 (31) / 9 (2) 84 (21) /
APOE genotype !4+ N (%) 147 (32) 349 (64) <0.001∗ 134 (29) 246 (61) <0.001∗
MMSE 27.93± 2.49 25.11± 4.29 <0.001∗ 28.09± 2.23 25.41± 4.26 <0.001∗
MCI, mild cognitive impairment; AD, Alzheimer’s disease, APOE, apolipoprotein E; CTL, cognitively healthy control; MMSE, Mini-Mental
State Examination. Mean± standard deviation. ∗Statistically significant by Mann-Whitney U, p < 0.05.
RESULTS
Clinical characteristics and inter-group
differences
The clinical characteristics of the Oxford and
Cardiff sample sets, stratified by amyloid status,
are presented in Table 1. Across both sample
sets, individuals with abnormal amyloid status were
older (p < 0.001), more frequently APOE !4 carriers
(p < 0.001), and had lower MMSE scores (p < 0.001)
compared to those with normal amyloid status.
Within the Oxford set only, individuals with abnor-
mal amyloid status were more frequently female
(p < 0.05) compared to those with normal amyloid
status.
Univariate statistics for amyloid status (high/low
group)
Cross-sectional comparisons of protein concen-
trations between normal and abnormal amyloid
status groups revealed seven proteins that remained
statistically significant after multiple testing correc-
tions (q < 0.05; ficolin-2 (FCN2), "2-microglobulin
(B2M), alpha-1 antitrypsin (A1AT), apolipoprotein
E (apoE), complement component 4 (C4), Cathepsin
D (CTSD), complement factor I (CFI), Table 2). Five
of these proteins have previously been discovered as
biomarkers of in vivo brain amyloid pathology in one
or more of our previous biomarker studies (FCN2,
B2M, A1AT, apoE, and C4), and all five replicate
the direction of change previously identified. Expres-
sion of cathepsin D has previously been found to be
decreased in AD fibroblasts, and here we show that
this protein is also decreased in plasma with increased
in vivo AD pathology [35]. CFI was previously found
as a biomarker for conversion from MCI to dementia,
with decreased plasma protein concentration in MCI
converters [36]. Therefore, the direction of change
identified in this study, decreased CFI with increased
pathology, agrees with this previous finding.
Logistic regression analysis was also performed
separately for each diagnostic group and APOE
!4 carrier groups (!4 non-carrier/!4 carrier). These
results are reported in Supplementary Tables 1–5.
ROC analysis was performed on each of the seven
proteins found to replicate direction of change to
determine their individual predictive ability for the
discrimination of normal/abnormal amyloid status
groups, and compared to the discriminant ability of
age. Table 3 displays the results of the ROC analysis
and Supplementary Figure 2 displays both the AUC
and corresponding 95% confidence interval of each
protein and age. The AUC for every protein is higher
than chance, even when including the lower end of
the confidence interval.
For these seven proteins, ROC analysis of amyloid
status classification was also performed separately for
each diagnostic group and APOE !4 carrier groups
(!4 non-carrier/!4 carrier). These results are reported
in Supplementary Tables 6 and 7.
Multi-protein classifier of amyloid
normal/abnormal status
It is possible, if the individual protein associa-
tions with in vivo AD pathology are independent
of each other, that a compound marker set of some
or all of these proteins would have greater predic-
tive value than any one protein alone. In order to
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Table 2
Logistic regression (age as covariate) results for each protein with
amyloid status as the outcome variable
Sample protein Logistic Regression
set beta p q N
O
xf
or
d
FCN2 0.466 0.000∗ 0.000∗ 824
FGG –0.071 0.300 0.521 891
Cystatin C –0.135 0.049∗ 0.124 898
Clusterin –0.138 0.045∗ 0.124 906
B2M –0.266 0.000∗ 0.004∗ 832
AGP 0.009 0.901 0.963 875
CP 0.028 0.679 0.780 883
A2M –0.017 0.813 0.900 896
ApoA1 –0.073 0.290 0.521 886
ApoC3 –0.001 0.991 0.991 900
apoE –0.220 0.002∗ 0.008∗ 901
TTR –0.039 0.572 0.772 901
CFH –0.049 0.475 0.701 907
CRP –0.139 0.049∗ 0.124 854
A1AT –0.213 0.004∗ 0.016∗ 784
PEDF –0.006 0.933 0.964 853
SAP –0.052 0.449 0.697 869
CC4 0.243 0.001∗ 0.005∗ 894
BDNF –0.036 0.603 0.778 887
Cathepsin D –0.238 0.001∗ 0.005∗ 880
sICAM-1 –0.148 0.033∗ 0.124 893
RANTES –0.100 0.146 0.309 905
NCAM 0.032 0.645 0.780 891
sVCAM-1 –0.071 0.302 0.521 891
PAI.1 –0.134 0.052 0.124 890
Ca
rd
iff
CR1 –0.077 0.378 0.617 770
TCC 0.112 0.149 0.309 770
CFB –0.042 0.567 0.772 788
CFI –0.284 0.000∗ 0.004∗ 754
Eotaxin 0.176 0.037∗ 0.124 749
MCP 0.031 0.680 0.780 769
∗Statistically significant < 0.05.
Table 3
AUC statistics per protein, for the classification of normal / abnormal brain amyloid status.
Abbreviations: AUC, area under the curve; CI, 95% confidence interval
Variable Optimal cutpoint Sensitivity Specificity AUC CI. CI.
low high
FCN2 24607094.990 0.448 0.783 0.640 0.593 0.690
Age 67.355 0.641 0.560 0.619 0.578 0.659
CFI 26793.107 0.547 0.623 0.585 0.531 0.639
C4 73789.784 0.436 0.713 0.580 0.533 0.630
B2M 4232.708 0.433 0.698 0.577 0.526 0.628
Cathepsin D 322.630 0.586 0.547 0.576 0.528 0.625
apoE 106.020 0.667 0.445 0.554 0.504 0.602
A1AT 1675622.528 0.765 0.333 0.552 0.506 0.606
test this, the seven proteins significant by logistic
regression after multiple testing corrections (q < 0.05;
FCN2, B2M, apoE, A1AT, CC4, cathepsin D, CFI)
were included in a logistic regression classifier,
along with age, to determine their predictive ability
for amyloid status when combined. After miss-
ing data were removed this 8-feature model was
tested on 374 individuals and achieved moderate
accuracy (AUC = 0.742 (Fig. 1, sensitivity = 0.682,
specificity = 0.704, LR = 2.3). In comparison, age
alone achieved an AUC = 0.617.
To determine how this 8-feature model performs
at different stages of the disease process and also in
APOE !4 carriers and non-carriers independently, we
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Fig. 1. ROC curve obtained for the 8-feature classifier for predic-
tion of amyloid normal/abnormal status. The 8-features included
were: FCN2, B2M, apoE, A1AT, CC4, cathepsin D, CFI, and age.
tested the classification ability of this model within
each separate diagnostic group and APOE !4 carriers
and non-carriers. Table 4 displays the performance
of this model within each group. The performance
within the AD-type dementia group could not be
accurately determined since removal of subjects with
missing data left only 5% of the AD-type dementia
cases as amyloid negative.
Relationship of classifier proteins with
continuous Aβ Z-score
We next wanted to determine whether this protein-
amyloid relationship remains consistent using the A"
Z-score (Table 5). All, except one protein (A1AT),
were significantly related to A" Z-score after testing
for multiple testing corrections (q < 0.05). A1AT was
tending towards significance (q = 0.061).
Relationship of classifier proteins with other
markers of in vivo AD pathology or disease
progression
In order to determine whether the classifier pro-
teins were specific to brain amyloid pathology or
if they could also perform as a biomarker of the
other key hallmark of AD, brain tau pathology, linear
regression was used to assess the continuous rela-
tionship with both p-tau and t-tau Z-scores (Table 5).
None of the proteins were significantly related to
either measure after multiple testing correction. We
then used a similar approach to examine their rela-
tionship to hippocampal volume and MMSE score,
and used logistic regression to examine their predic-
tive ability for MCI conversion to dementia (Table 5).
FCN2 displayed a significant relationship with all
three measures (q < 0.05). CFI was found to be sig-
nificantly related to both baseline MMSE and MCI
conversion to dementia (q < 0.05). A1AT was found
to be significantly related to hippocampal volume
only (q < 0.05).
DISCUSSION
We have previously used a pathology endophe-
notype approach to discover plasma proteomic
biomarkers designed to be predictive of in vivo AD
pathology and disease progression. The aim of the
present study was to replicate these previously iden-
tified candidate biomarkers in a large multi-center
pragmatic sample collection collated from multiple
cohorts, as well as to identify a plasma proteomic
panel that could classify individuals into high or low
brain amyloid groups. Our results show that in around
1,000 samples from multiple studies across Europe,
seven biomarkers replicate, and we confirm a panel
of proteins that identify abnormal levels of in vivo
amyloid pathology with a sensitivity of 0.682 and a
specificity of 0.704. While we chose to maximize the
Table 4
ROC and AUC statistics for the 8-feature model for the classification of amyloid status within
each diagnostic group, and APOE !4 carriers and non-carriers
AUC Sensitivity Specificity LR N
Whole cohort (AD, MCI, CTL) 0.742 0.682 0.704 2.30 374
MCI 0.743 0.658 0.785 3.06 193
CTL 0.768 0.682 0.776 3.04 142
MCI and CTL combined 0.724 0.677 0.661 2.00 335
APOE !4 non-carriers 0.736 0.681 0.725 2.47 199
APOE !4 carriers 0.836 0.757 0.767 3.25 175
MCI, mild cognitive impairment; AD, Alzheimer’s disease, APOE, apolipoprotein E; CTL, cogni-
tively healthy control; AUC, area under the curve; LR, likelihood ratio.
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Youden’s index, which gave a balanced compromise
between false negative and false positive results, simi-
larly, any other operational point may also be suitable,
depending on the clinical utility and priorities. More-
over, the model has predictive value in both APOE
!4 carrier and non-carrier individuals generating a
biological predictor that could be used to reduce the
screen failure rate in clinical trials.
The final 7-protein biomarker panel consists
of: "2-microglobulin (B2M), cathepsin D (CTSD),
ficolin-2 (FCN2), complement component 4 (C4),
alpha-1 antitrypsin (A1AT), complement factor I
(CFI), and apolipoprotein E (apoE). We did not find
any significant improvement to AUC by introducing
standardized quadratic terms for each of the signifi-
cant variables. Specifically, our variables are: ‘Age’
and seven proteins: ‘FCN2’, ‘B2M’, ‘ApoE’, ‘A1AT’,
‘CC4’, CathepsinD’, and ‘CFI’. Using them as a lin-
ear combination, we achieved AUC = 0.742 and the
most significant ones (p < 0.001) were Age, FCN2,
and B2M. Their quadratic terms were found to be
both, small (effect size) and statistically insignifi-
cant. Although initial discovery-phase studies used
an unbiased approach to identify proteins that have
a relationship with AD and its pathology, it is note-
worthy that the resulting biomarker candidates are
also biologically relevant to the disease process. B2M
shares structural characteristics with fibrillar A" [37]
and is one of a number of proteins that form amyloid
deposits. Cathepsin D is increased in tangle bearing
neurons [38], a process that might be induced by A"
[39]. Ficolin-2 and mannose-binding lectin (MBL)
are both activators of the lectin complement pathway
[40] and CSF MBL levels have been shown to be
reduced in AD [41]. The complement proteins (C4
and CFI) are two members of a pathway repeatedly
shown to be associated with AD through genetics and
neuropathology as well as from biomarker studies
[42]. A1AT is an acute phase chemoreactant that is
metabolized by the serpin enzyme complex (SEC)
and hence might compete with and affect the activ-
ity of another SEC ligand, A" [43]. The relationship
between the APOE !2/!3/!4 polymorphism and AD
is well established and complementary to our finding
here that apoE protein is clearly a marker of amyloid
load.
Recently, Nakamura et al. (2018) published an
important study demonstrating that A" fragments
can be reliably detected in blood and perform as
well as current CSF biomarkers for predicting brain
amyloid [44]. This approach using immunoprecipi-
tation combined with mass spectrometry (IP+MS),
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was able to predict brain amyloid status with up to
90% accuracy. This finding builds upon other recent
work by Ovod et al. (2017) who also used an IP+MS
technique to identify blood A" with high concor-
dance to amyloid PET [45]. While these papers are
important in demonstrating the value of blood A"
as a biomarker tool for brain pathology, replication
in more studies with larger sample sizes is needed,
and the proteomic technology employed will require
refinement to enable implementation at scale. Nev-
ertheless, these studies provide considerable further
proof of concept for AD blood biomarkers. While the
accuracy rates reported in our study are not as high as
those reported when measuring blood A" levels, we
are still able to achieve a level of accuracy sufficient
to make a substantial impact upon the cost efficiency
of clinical trials while using immunocapture—a prac-
tical and low-cost assay technology already in very
wide use in both clinical and research laboratories.
Given that sample collection and storage pro-
tocols differed across the 11 cohorts included in
the EMIF-AD MBD study [17], this pragmatic
meta-collection reflects the challenges faced by any
putative biomarker in the real-world of multi-site,
multi-national clinical studies, and even more so in
clinical practice, where standardization of sample
collection is sought but rarely achieved. Replication
of any putative biomarker set in such a collection of
samples has a higher prior probability of effective
utility in practice than replication in a single cohort
or single site study with a fully standardized sam-
ple collection procedure. Nonetheless, the limitations
of this study are also acknowledged; this study was
designed to determine whether candidate biomark-
ers replicate in their ability to predict amyloid, it
was not designed to determine the real-world value
of the biomarkers or the biomarker panel they form
for clinical trial screening. Selecting half of the sam-
ples from people with high amyloid enables proof of
concept but clearly random prediction will already
identify 50% of those with amyloid correctly. Addi-
tionally, missing data (4–11% per protein as a result
of variable sample volume and quality and occasional
assay performance failure) meant that when combin-
ing multiple proteins together in a biomarker panel
the overall sample size with complete data was sig-
nificantly reduced. However, even in this reduced
sample set with 50% prediction accuracy possible by
chance, the likelihood ratio with our biomarker panel
is 2.3 in the whole cohort and 3 for preclinical disease,
suggesting approximately a 15% and 20% improve-
ment in detection respectively [46]. With a typical
amyloid positivity rate of 30% and a representative
cost of $3500 for an amyloid PET scan, recruiting
1,000 amyloid positive subjects would require 3,333
subjects at a total cost of $11.7 million. Pre-screening
can reduce this cost. Utilizing the optimal model sen-
sitivity and specificity values (Table 4) and assuming
an assay cost of $150, the total cost of recruiting
would be $7.8 million and require pre-screening 4900
subjects. Going further, model sensitivities and speci-
ficities are based on cut-offs that can be optimized
to be fit-for-purpose for a given application. For the
present model, optimizing the cut-off for minimum
total cost would yield a sensitivity of 34% and a speci-
ficity of 93% requiring pre-screening 9700 subjects
with a total recruitment cost of $6.6 million. When
the positive prevalence is low and the cost of the truth
assay is high relative to the pre-screen, such economic
optimizations often favor specificity to reject a large
portion of true negatives to save operating costs. Such
economic trade-offs require a larger screening popu-
lation and have a higher false negative rate. Screening
in medical practice, however, favors higher sensitivity
to optimize the yield of subjects for intervention. In
short, low-cost pre-screening applications can save
money and be tuned as needed for the application
context.
To summarize, our overall goal is to facilitate
clinical trials by contributing to rapid and effective
selection of research participants most likely to have
brain amyloid pathology and hence reducing screen
failure rates, reducing cost and time of trial start-
up and reducing exposure of potential participants to
PET imaging or CSF lumbar puncture. In order to do
this, we have previously investigated, discovered, and
replicated plasma protein biomarkers that could be
implemented as a clinical trial entry criterion to triage
potential participants for amyloid PET or CSF mea-
sures. In the current study, seven of these biomarkers
are replicated in a large, multi-center cohort. These
seven proteins form a biomarker panel that is the
product of over a decade of research, is biologically
relevant and measurable using practical immunocap-
ture arrays, and could significantly reduce the cost
incurred to clinical trials by screen failure because of
absence of amyloid pathology.
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